Eledon Pharmaceuticals (ELDN) Expected to Post Quarterly Earnings on Thursday

Eledon Pharmaceuticals (NASDAQ:ELDN) is anticipated to announce its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Eledon Pharmaceuticals to announce earnings of ($0.1580) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.11).

Eledon Pharmaceuticals Stock Performance

Shares of ELDN stock opened at $3.75 on Wednesday. Eledon Pharmaceuticals has a fifty-two week low of $1.35 and a fifty-two week high of $4.60. The firm has a market capitalization of $289.46 million, a price-to-earnings ratio of -4.87 and a beta of 0.98. The stock’s 50-day simple moving average is $3.72 and its 200-day simple moving average is $3.26.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eledon Pharmaceuticals in a research note on Wednesday, June 24th. Rodman & Renshaw started coverage on shares of Eledon Pharmaceuticals in a research note on Tuesday, July 21st. They set a “buy” rating and a $12.00 price target on the stock. Finally, Wall Street Zen cut shares of Eledon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Eledon Pharmaceuticals has a consensus rating of “Hold” and an average target price of $9.67.

Institutional Investors Weigh In On Eledon Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ELDN. First Light Asset Management LLC boosted its position in Eledon Pharmaceuticals by 11.7% in the second quarter. First Light Asset Management LLC now owns 2,600,498 shares of the company’s stock valued at $7,047,000 after buying an additional 271,730 shares during the last quarter. Ensign Peak Advisors Inc increased its holdings in Eledon Pharmaceuticals by 94.9% in the 4th quarter. Ensign Peak Advisors Inc now owns 2,464,919 shares of the company’s stock worth $3,722,000 after buying an additional 1,200,000 shares during the period. Zimmer Partners LP raised its position in Eledon Pharmaceuticals by 30.6% during the 4th quarter. Zimmer Partners LP now owns 2,384,228 shares of the company’s stock worth $3,600,000 after buying an additional 559,228 shares during the last quarter. Sphera Funds Management LTD. boosted its holdings in shares of Eledon Pharmaceuticals by 97.4% in the 4th quarter. Sphera Funds Management LTD. now owns 2,132,131 shares of the company’s stock valued at $3,220,000 after acquiring an additional 1,051,898 shares during the last quarter. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Eledon Pharmaceuticals in the 4th quarter valued at $2,751,000. Institutional investors and hedge funds own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.